Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. Feb. 18, 2019. Michael Carome.

Executive Summary

At a recent meeting, a US FDA advisory committee cautioned the agency to very carefully consider risks and benefits prior to agency approval of any new pelvic mesh products. See what Public Citizen's Michael Carome said about it here.

“Thousands of women have been harmed, many permanently, by pelvic mesh. We urge the FDA to reject the PMA applications for the three products still on the market, effectively banning them." –Michael Carome, director, Public Citizen's Health Research Group

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel